Reshaping the TME to enhance checkpoint blockade in ENKTL
In this issue of Blood, Kim et al1 present compelling findings from a phase 2 trial exploring the combination of cemiplimab, an anti–programmed death-1 (an
Related Articles
Sequential BCMA CAR-T Cell Therapy in Refractory Multiple Myeloma
Key Points. Sequential treatment with commercially available BCMA-directed CAR-T therapy in refractory myeloma is safe and efficaciousDuration of response
Real-world data provide a CARbon copy for ide-cel
In this issue of Blood, Sidana et al report the largest real-world analysis of chimeric antigen receptor T-cell (CAR-T) therapy in multiple myeloma (MM), c
ASH Clinical News Seeks Associate Editors for 2026-2028 Terms | ASH Clinical News | American Society of Hematology
The American Society of Hematology (ASH) is in search of Associate Editors to join ASH Clinical News, the Society’s monthly news magazine for the broader…
Real-world data provide a CARbon copy for ide-cel
In this issue of Blood, Sidana et al report the largest real-world analysis of chimeric antigen receptor T-cell (CAR-T) therapy in multiple myeloma (MM), c
From CyBorD to Dara-CyBorD: ASCT Utilization Trends in AL Amyloidosis, A 15-Year Analysis
Key Points. ASCT for AL amyloidosis decreased significantly (71% average annual reduction) with the introduction of Dara-CyBorDASCT now targets patients wi
Efficacy and Safety of BCMA Nanobody CAR-T Cell Therapy in Relapsed or Refractory Plasma Cell Myeloma
Key Points. Dual nanobody VHHs (dVHHs) targeting BCMA, achieved a high ORR in the treatment of relapsed or refractory plasma cell myeloma patients.Its effi
